Biovica International AB (OSTO:BIOVIC B) Cash-to-Debt : 12.81 (As of Jan. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Biovica International AB Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Biovica International AB's cash to debt ratio for the quarter that ended in Jan. 2024 was 12.81.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Biovica International AB could pay off its debt using the cash in hand for the quarter that ended in Jan. 2024.

The historical rank and industry rank for Biovica International AB's Cash-to-Debt or its related term are showing as below:

OSTO:BIOVIC B' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.8 Med: 56.87 Max: No Debt
Current: 12.81

During the past 9 years, Biovica International AB's highest Cash to Debt Ratio was No Debt. The lowest was 3.80. And the median was 56.87.

OSTO:BIOVIC B's Cash-to-Debt is ranked better than
58.41% of 1486 companies
in the Biotechnology industry
Industry Median: 6.9 vs OSTO:BIOVIC B: 12.81

Biovica International AB Cash-to-Debt Historical Data

The historical data trend for Biovica International AB's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Biovica International AB Cash-to-Debt Chart

Biovica International AB Annual Data

Trend

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

11.81

60.07

6.78

10.94

Biovica International AB Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cash-to-Debt	Get a 7-Day Free Trial															13.09	10.94	7.69	5.01	12.81

Competitive Comparison of Biovica International AB's Cash-to-Debt

For the Biotechnology subindustry, Biovica International AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biovica International AB's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biovica International AB's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Biovica International AB's Cash-to-Debt falls into.

Biovica International AB Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Biovica International AB's Cash to Debt Ratio for the fiscal year that ended in Apr. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	114.327	/	(3.149	+	7.304)
	=	10.94

Biovica International AB's Cash to Debt Ratio for the quarter that ended in Jan. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	105.238	/	(3.416	+	4.802)
	=	12.81

Biovica International AB (OSTO:BIOVIC B) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Biovica International AB Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Biovica International AB's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Biovica International AB (OSTO:BIOVIC B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biovica International AB (OSTO:BIOVIC B) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

9II:Germany

Address

Dag Hammarskjolds vag 54B, Uppsala Science Park, Uppsala, SWE, 752 37

Website

http://www.biovica.com

Biovica International AB is a biotech company. It develops and commercializes blood-based diagnostic tests with biomarkers that improve monitoring and evaluation of modern cancer treatments. Through collaboration with world- leading cancer institutes and pharmaceutical companies, it promotes the trend in healthcare for personalized treatment, with a primary focus on patient survival and benefits to society. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.

Biovica International AB (OSTO:BIOVIC B) Headlines

No Headlines